Unique ID issued by UMIN | UMIN000020235 |
---|---|
Receipt number | R000023369 |
Scientific Title | Exploratory Clinical Trial for Efficacy and Safety of Short-term (3 days) Enoxaparin on Prevention of Venous Thromboembolism after Gastric Cancer Surgery |
Date of disclosure of the study information | 2016/01/01 |
Last modified on | 2018/06/20 00:06:19 |
Exploratory Clinical Trial for Efficacy and Safety of Short-term (3 days) Enoxaparin on Prevention of Venous Thromboembolism after Gastric Cancer Surgery
Efficacy and Safety of Short-term (3 days) Enoxaparin on Gastric Cancer Surgery
Exploratory Clinical Trial for Efficacy and Safety of Short-term (3 days) Enoxaparin on Prevention of Venous Thromboembolism after Gastric Cancer Surgery
Efficacy and Safety of Short-term (3 days) Enoxaparin on Gastric Cancer Surgery
Japan |
Gastric cancer
Gastrointestinal surgery |
Malignancy
YES
To evaluate the efficacy and safety of 3-day use of low molecular weight heparin (enoxaparin) combined with intermittent pneumatic compression on prevention of postoperative venous thromboembolism for gastric cancer patients over 40 years of age who are planned to receive gastrectomy
Safety,Efficacy
Exploratory
Explanatory
Phase II
Incidence of venous thromboembolism at 8 to 14 days after surgery
Incidence of bleeding-related adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Device,equipment |
Subcutaneous injection of enoxaparin (2000IU, twice a day, from night of the 1st day to morning of the 4th day, 6 times in total) in combination with intermittent pneumatic compression
40 | years-old | <= |
Not applicable |
Male and Female
1) Patients with histologically-diagnosed gastric cancer who are planned to receive total, distal, proximal or partial gastrectomy (surgical approach do not matter)
2) Patients over 40 years of age
3) Patients who can give written informed concent
1) Patients with past history of venous thromboembolism
2) Patients with past history of allergic reaction to heparin or heparinoid (including low molecular weight heparin)
3) Patients with active bleeding (except for bleeding from gastric cancer planned to be resected by surgery)
4) Patients with acute bacterial endocarditis
5) Patients with severe renal dysfunction (Ccr < 30mL/min)
6) Patients with past history of heparin-induced thrombocytopenia
7) Patients who are otherwise judged by the investigator as unsuitable for enrollment
70
1st name | |
Middle name | |
Last name | Toshiyoshi Fujiwara |
Okayama University
Gastroenterological Surgery
2-5-1 Shikata-cho, Kita-ku, Okayama
086-235-7257
toshi_f@md.okayama-u.ac.jp
1st name | |
Middle name | |
Last name | Shinji Kuroda |
Okayama University
Gastroenterological Surgery
2-5-1 Shikata-cho, Kita-ku, Okayama
086-235-7257
shinkuro@okayama-u.ac.jp
Okayama University
Gastroenterological Surgery, Okayama University
Self funding
NO
2016 | Year | 01 | Month | 01 | Day |
Unpublished
Completed
2015 | Year | 12 | Month | 15 | Day |
2016 | Year | 03 | Month | 16 | Day |
2015 | Year | 12 | Month | 16 | Day |
2018 | Year | 06 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023369